These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18164835)

  • 1. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
    Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
    Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
    Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
    Murata R; Siemann DW; Overgaard J; Horsman MR
    Radiother Oncol; 2001 Aug; 60(2):155-61. PubMed ID: 11439210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
    J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of anti-vascular therapy with texture analysis.
    Chen G; Jespersen S; Pedersen M; Pang Q; Horsman MR; Stødkilde Jørgensen H
    Anticancer Res; 2005; 25(5):3399-405. PubMed ID: 16101155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy.
    Murata R; Overgaard J; Horsman MR
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1018-24. PubMed ID: 11704326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
    Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H
    Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
    Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
    Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
    Hokland SL; Horsman MR
    Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
    Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
    Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure.
    Ley CD; Horsman MR; Kristjansen PE
    Neoplasia; 2007 Feb; 9(2):108-12. PubMed ID: 17356706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
    Murata R; Tsujitani M; Horsman MR
    Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor.
    Bentzen L; Vestergaard-Poulsen P; Nielsen T; Overgaard J; Bjørnerud A; Briley-Saebø K; Horsman MR; Ostergaard L
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1208-15. PubMed ID: 15752903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
    Dowlati A; Robertson K; Cooney M; Petros WP; Stratford M; Jesberger J; Rafie N; Overmoyer B; Makkar V; Stambler B; Taylor A; Waas J; Lewin JS; McCrae KR; Remick SC
    Cancer Res; 2002 Jun; 62(12):3408-16. PubMed ID: 12067983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.
    Faccioli N; Marzola P; Boschi F; Sbarbati A; D'Onofrio M; Pozzi Mucelli R
    Radiol Med; 2007 Apr; 112(3):319-28. PubMed ID: 17440699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
    Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
    J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.
    Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Ley CD; Kristjansen PE; Horsman MR
    Acta Oncol; 2010 Oct; 49(7):906-13. PubMed ID: 20831477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer.
    Zahra MA; Tan LT; Priest AN; Graves MJ; Arends M; Crawford RA; Brenton JD; Lomas DJ; Sala E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):766-73. PubMed ID: 19019563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of vascular targeting agents with thermal or radiation therapy.
    Horsman MR; Murata R
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1518-23. PubMed ID: 12459380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.